FGF23 and chronic kidney disease: Indeed, De Jong and colleagues52 reported on small albeit significant increases in serum phosphate (9%), FGF‐23 (19%), and PTH (16%) in a cohort of 31 patients with T2D complicated by CKD stages 2 to 4 and albuminuria who were treated with dapagliflozin for 6 weeks.